Drug Search Results
More Filters [+]

Esmethadone

Alternative Names: esmethadone, rel-1017, rel1017, rel 1017
Latest Update: 2024-11-12
Latest Update Note: Clinical Trial Update

Product Description

REL-1017 is a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker in phase 3 clinical trials for the treatment of Major Depressive Disorder (MDD). REL-1017 works with a MOA markedly different from standard serotoninergic antidepressants. (Sourced from: https://www.relmada.com/science)

Mechanisms of Action: NMDA Blocker

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Depressive Disorder|Depressive Disorder, Major *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Relmada
Company Location: NEW YORK NY 10022
Company CEO: Sergio Traversa
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Esmethadone

Countries in Clinic: United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Depressive Disorder, Major

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

RELIANCE-II

P3

Recruiting

Depressive Disorder, Major

2024-12-01

RELIGHT

P3

Recruiting

Depressive Disorder, Major

2024-12-01

RELIANCE-OLS

P3

Completed

Depressive Disorder, Major

2023-07-27

Reliance I

P3

Completed

Depressive Disorder, Major

2022-11-01

Recent News Events